HORSHAM, Pa., Oct. 26 /PRNewswire-FirstCall/ -- Neose Technologies, Inc. today announced that it will release financial results for the third quarter of 2005 on Wednesday, November 2, 2005, after the U.S. financial markets close. The company will host a conference call at 5:00 p.m. (ET) the same day to discuss financial results and update investors on company developments. The call is expected to last approximately 30 minutes and will include prepared remarks by Neose management with a subsequent question and answer period.
The dial-in number for domestic callers is (800) 946-0705. The dial-in number for international callers is (719) 457-2637. A replay of the call will be available for 7 days beginning approximately three hours after the conclusion of the call. The replay number for domestic callers is (888) 203- 1112, using the passcode 1159649. The replay number for international callers is (719) 457-0820, also using the passcode 1159649. The call will also be webcast live through the Company’s website via the following link:
http://phx.corporate-ir.net/phoenix.zhtml?c=60494&p=irol-calendar
To listen to the live call, please go to the web site at least fifteen minutes early to register, download, and install any necessary audio software. For those who cannot listen to the live broadcast, a replay will be available shortly after the call.
Neose is a biopharmaceutical company using its proprietary enzymatic technologies to develop improved drugs, focusing primarily on therapeutic proteins. Neose uses its GlycoAdvance(R) and GlycoPEGylation(TM) technologies to develop improved versions of drugs with proven safety and efficacy. Neose intends to apply its technologies to products it is developing on its own and to products it co-develops and co-owns with others. It also expects to make its technologies available, through strategic partnerships, to improve the products of other parties. Neose’s first two proprietary candidates are NE- 180 (GlycoPEG-EPO), a long-acting version of erythropoietin, and GlycoPEG- GCSF, a long-acting version of granulocyte colony stimulating factor (G-CSF).
CONTACTS: Neose Technologies, Inc. A. Brian Davis Sr. Vice President and Chief Financial Officer Barbara Krauter Manager, Investor Relations (215) 315-9000 E-mail: info@neose.com For more information, please visit http://www.neose.com.
Audio: http://phx.corporate-ir.net/phoenix.zhtml?c=60494&p=irol-calendarNeose Technologies, Inc.
CONTACT: A. Brian Davis, Sr. Vice President and Chief Financial Officer,or Barbara Krauter, Manager, Investor Relations, both of NeoseTechnologies, Inc., +1-215-315-9000, E-mail: info@neose.com
Web site: http://www.neose.com/
